Arbutus to Present at Chardan’s Genetic Medicines Conference

From Startup Arbutus Bio

Link to Full Article: http://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-chardans-genetic-medicines-conference

WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 2:45 pm – 3:10 pm ET in New York.
A live webcast of the fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.  A replay of the webcast will be available for 90 days following the live presentation.
About Arbutus
Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Mark MurrayPresident and CEOPhone: 604-419-3200 Email: ir@arbutusbio.com
Pam MurphyInvestor Relations ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com

Source: Arbutus Biopharma Corporation

Please visit their site for more information: Arbutus Bio.com

All,Biotechnology,Healthcare News,Startup News
2018-10-03 05:52:01